Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
5 and 10 mg Donepezil as well as 4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
New Active Ingredient + Innovative Drug Delivery System = Business Success More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Fentanyl and Buprenorphine are indicated for the management of severe pain in patients who require continuous opioid analgesia More
Adjuvant that induces a potent antigen-specific CD8 cytotoxic T-cell response with long lasting immunity More
NNRTI as antagonists of cell proliferation and inducers of cell differentiation. More
Biosimilar to Epogen®/Eprix®; available for purchase in bulk or finished product form More
Biosimilar to Neupogen®; available in bulk or finished More
Your selection
Browse By
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us